FIG. 7.

The number of antigen-specific CD8⁺ T cells during secondary LCMV infection is unaffected by MnTBAP treatment. C57BL/6 LCMV Armstrong immune mice were treated with either vehicle or 5 mg of MnTBAP/kg and then infected with LCMV clone 13 (A). A maintenance dose was administered every 24 h. At the indicated time points, mice were sacrificed, the spleen was removed, and cells were stained with anti-CD8α and either anti-CD44 (B), D^bGP33-41 (C), D^bNP396-404 (D), or D^bGP276-286 (E). The numbers of activated (B) and antigen-specific CD8⁺ T cells (C-E) were quantitated, and the averages and standard deviations are shown. Six to eight mice were analyzed at each time point. *, significant difference between vehicle- and MnTBAP-treated mice; P ≤ 0.05.